Investigating a new treatment for alcoholic liver disease
Fumarates for Alcoholic Liver Disease
This study is looking at a new treatment called nicotinamide fumarate (NMF) to see if it can help people with alcoholic liver disease, and it will compare how well it works against another drug, RTA408, using mice to learn more about how these treatments might help in the future.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10700042 on NIH RePORTER |
What this research studies
This research focuses on alcoholic liver disease (ALD), a serious condition with no effective therapies currently available. The team is exploring a novel compound called nicotinamide fumarate (NMF), which has shown promise in preliminary studies for reducing liver injury in animal models. The research will compare the effectiveness of NMF with another drug, RTA408, and aims to understand the underlying mechanisms of how these treatments work. By using mouse models, the researchers hope to pave the way for future clinical applications that could benefit patients suffering from ALD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcoholic liver disease who may benefit from new therapeutic options.
Not a fit: Patients with liver disease caused by factors other than alcohol may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new effective treatment for patients with alcoholic liver disease.
How similar studies have performed: While the approach of using fumarates for liver disease is relatively novel, there have been successful applications of similar compounds in other medical conditions.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Jiang, Xiaosong Joy — University of California at Davis
- Study coordinator: Jiang, Xiaosong Joy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.